Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results
Daix (France), Long Island City (New York, United States), September 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company’s 2022 half-year financial results on Thursday, September 22, 2022.
Inventiva’s 2022 half-year financial results will be published on Wednesday, September 21, 2022
at 4:00 pm (New York), 10:00 pm (Paris).
Frédéric Cren, Chairman, CEO and cofounder of Inventiva, Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, Jean Volatier, Chief Financial Officer of Inventiva, and Michael Cooreman, Chief Medical Officer of Inventiva, will hold a conference call in English, followed by a Q&A session, on Thursday, September 22, 2022 at8:00 am (New York), 2:00 pm (Paris).
The conference call and the slides of the presentation will be webcast live at: https://edge.media-server.com/mmc/p/v5uzhkr8 and also available on Inventiva’s onwards in the “Investors” – “Financial results” section.
In order to receive the conference access information necessary to join the conference call, it is required to register in advance using the following link: https://register.vevent.com/register/BI3a0c8ee6960a4b7a9db4026550ff3f51.
In the 10 minutes prior to the call start time, participants will need to use the conference access information provided in the e-mail received at the point of registering (dial-in number and access code).
A replay of the conference call and the presentation will be available after the event at: http://inventivapharma.com/investors/financial-results-presentations/.
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies.
The Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases that resulted in the discovery of the drug candidate cedirogant (ABBV-157), an oral RORγ inverse agonist which is being evaluated in a Phase IIb clinical trial, led by AbbVie, in adult patients with moderate to severe chronic plaque psoriasis. Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult mucopolysaccharidoses (MPS) VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program.
The Company has a scientific team of approximately 80 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.
Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com.
VP of Global External Affairs
+1 240 620 9175
Tristan Roquet Montegon /
Aude Lepreux / Matthieu Benoist
+33 1 53 96 83 83
|Westwicke, an ICR Company|
Patricia L. Bank
+1 415 513 1284
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Notice on Convocation of Extraordinary General Meeting of Shareholders of AB Klaipėdos nafta30.9.2022 08:00:00 CEST | Press release
Notice is hereby given that on the initiative and by the resolution of the Board of AB Klaipėdos nafta, legal entity code 110648893, with the registered office at Burių str. 19, Klaipeda (hereinafter - the Company), Exraordinary General Meeting of Shareholders of the Company will be held on 20 October 2022 at 1:00 p.m. The meeting will be held in the Company’s office at Buriu str. 19, Klaipeda, in the administrative office of the Company (in the hall of the meeting on the 2nd floor). Agenda of the meeting: Approval of amendment of Remuneration Policy of AB Klaipėdos nafta. The shareholders will be registered from 12:00 a.m. to 12:55 p.m. The persons intending to participate in the meeting shall have a personal ID document (an authorized representative shall have an authorization approved under the established procedure. The natural person’s authorization shall be notarized. An authorization issued in a foreign state shall be translated into the Lithuanian language and legalized under t
Kitron: Ferroamp signs production agreement with Kitron30.9.2022 08:00:00 CEST | Press release
(2022-09-30) Kitron has entered into a production agreement with Ferroamp, a rapidly growing Swedish greentech company. The value of the agreement is expected to reach approximately NOK 90 million in 2023 and NOK 350 million over a three-year period. Ferroamp has developed EnergyHub, a system that controls electricity use using a patented DC technology, so that property owners can get more out of their solar panels and integrate electric car charging and energy storage. During the first half of 2022, Ferroamp increased its sales by 60 percent and is now planning an international launch. “Ferroamp continues to expand its operations through collaborations with strategic partners. We are delighted to have signed an agreement with Kitron, which has a leading position in electronics production and has the capacity to produce large volumes of EnergyHub systems for our residential customers,” says Krister Werner, CEO of Ferroamp. The EnergyHub system is available for both commercial propertie
Kitron: Ferroamp inngår produksjonsavtale med Kitron30.9.2022 08:00:00 CEST | Pressemelding
(2022-09-30) Kitron har inngått en produksjonsavtale med Ferroamp, et raskt voksende svensk miljøteknologiselskap. Verdien av avtalen forventes å være rundt 90 millioner kroner i 2023 og 350 millioner kroner over en treårsperiode. Ferroamp har utviklet EnergyHub, et system som styrer strømforbruk ved hjelp av patentert DC-teknologi slik at eiendomsbesittere kan utnytte solcellepanelene sine bedre samt integrere elbillading og energilagring. I løpet av første halvår 2022 økte Ferroamp salget med 60 prosent og planlegger nå en internasjonal lansering. – Ferroamp fortsetter å utvide sin virksomhet gjennom samarbeid med strategiske partnere. Vi er glade for å ha inngått en avtale med Kitron, som har en ledende posisjon innen elektronikkproduksjon og kapasitet til å produsere store volumer EnergyHub-systemer for våre kunder i boligmarkedet, sier Krister Werner, administrerende direktør i Ferroamp. EnergyHub-systemet er tilgjengelig for både næringseiendommer og flerfamiliebygg, og EnergyHub
Equinor utnevner Torgrim Reitan til ny finansdirektør30.9.2022 08:00:00 CEST | Pressemelding
Torgrim Reitan er utnevnt til ny konserndirektør for finans i Equinor (OSE: EQNR, NYSE: EQNR), med virkning fra 6. oktober 2022. Reitan etterfølger Ulrica Fearn som har besluttet å slutte i selskapet for å bli finansdirektør i et selskap utenfor Equinor. Ulrica Fearn vil være tilgjengelig for å sikre en god overlevering til Reitan inntil videre. – Jeg er veldig glad for å ønske Torgrim tilbake konsernledelsen. Torgrim har en veldig solid bakgrunn for å ta ansvaret som finansdirektør i Equinor, og for å være en drivkraft i arbeidet med å nå vår ambisjon om å være et ledende selskap i det grønne skiftet. I dagens energikrise er det en styrke å ha Torgrim I toppledelsen, med hans erfaring brede erfaring som finansdirektør, fra vår oppstrømsvirksomhet, fra forretningsområdet for trading og drift av naturgass, og sist fra arbeidet med å akselerere veksten i vår fornybarvirksomhet, sier Anders Opedal, konsernsjef i Equinor. – Jeg ser frem til å bli en del av konsernledelsen, og til å jobbe t
Equinor appoints Torgrim Reitan as new Chief Financial Officer30.9.2022 08:00:00 CEST | Press release
Torgrim Reitan has been appointed Chief Financial Officer and executive vice president in Equinor (OSE: EQNR, NYSE: EQNR), with effect from 6 October 2022. Reitan succeeds Ulrica Fearn who has decided to leave the company to pursue a CFO opportunity outside the company. Ulrica Fearn will be available to secure a good hand over to her successor until further notice. “I am very pleased to welcome Torgrim back to the Corporate Executive Committee. Torgrim has a very strong background to take on the complex challenge as CFO in Equinor, as we progress our ambition to be a leading company in the energy transition. In the current energy crisis, it is a definite strength to have Torgrim in my top management team, with his experience as CFO, from our upstream business, from trading and operations of natural gas, and lastly from the acceleration of growth in our renewables business,” says Anders Opedal, president and CEO of Equinor. “I look very much forward to joining the CEC and to work closel